Double placebo design in a prevention trial for Alzheimer's disease - PubMed (original) (raw)

Clinical Trial

Double placebo design in a prevention trial for Alzheimer's disease

Barbara K Martin et al. Control Clin Trials. 2002 Feb.

Abstract

The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) is designed to compare two nonsteroidal anti-inflammatory agents against placebo. A placebo control for two active treatments can be achieved in several ways, each of which may have different implications for the logistics of drug supply, enrollment, adherence to treatment, and the validity of specific treatment comparisons. The authors outline the placebo designs considered in ADAPT, discuss their advantages and disadvantages, and provide their rationale for and the consequences of the selection of the double placebo design.

PubMed Disclaimer

Similar articles

• Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).
  Meinert CL, Breitner JC. Meinert CL, et al. Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S7-S14. doi: 10.1016/j.jalz.2007.10.007. Epub 2007 Dec 21. Alzheimers Dement. 2008. PMID: 18632005
• [The possible suppression of Alzheimer's disease by nonsteroidal anti-inflammatory drugs].
  de Jong D, Jansen RW, Verbeek MM, Kremer HP. de Jong D, et al. Ned Tijdschr Geneeskd. 2002 Nov 2;146(44):2074-8. Ned Tijdschr Geneeskd. 2002. PMID: 12448960 Review. Dutch.
• [Anti-inflammatory drug therapy for prevention of Alzheimer's Disease?].
  Sulkava R. Sulkava R. Duodecim. 1998;114(20):2025, 2027. Duodecim. 1998. PMID: 11717722 Finnish. No abstract available.
• The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease.
  Breitner JC. Breitner JC. Annu Rev Med. 1996;47:401-11. doi: 10.1146/annurev.med.47.1.401. Annu Rev Med. 1996. PMID: 8712791 Review.
• Inflammatory processes and Alzheimer's disease.
  Walsh S, Aisen PS. Walsh S, et al. Expert Rev Neurother. 2004 Sep;4(5):793-8. doi: 10.1586/14737175.4.5.793. Expert Rev Neurother. 2004. PMID: 15853506 Review.

Cited by

• Blinding in pharmacological trials: the devil is in the details.
  Wan M, Orlu-Gul M, Legay H, Tuleu C. Wan M, et al. Arch Dis Child. 2013 Sep;98(9):656-9. doi: 10.1136/archdischild-2013-304037. Epub 2013 Jul 29. Arch Dis Child. 2013. PMID: 23898156 Free PMC article. No abstract available.
• Extended results of the Alzheimer's disease anti-inflammatory prevention trial.
  Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mullan MJ, Sabbagh M, Tariot PN; ADAPT Research Group. Breitner JC, et al. Alzheimers Dement. 2011 Jul;7(4):402-11. doi: 10.1016/j.jalz.2010.12.014. Alzheimers Dement. 2011. PMID: 21784351 Free PMC article. Clinical Trial.
• Arabidopsis thaliana extracts optimized for polyphenols production as potential therapeutics for the APOE-modulated neuroinflammation characteristic of Alzheimer's disease in vitro.
  Ghura S, Tai L, Zhao M, Collins N, Che CT, Warpeha KM, LaDu MJ. Ghura S, et al. Sci Rep. 2016 Jul 7;6:29364. doi: 10.1038/srep29364. Sci Rep. 2016. PMID: 27383500 Free PMC article.
• Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results.
  ADAPT Research Group; Meinert CL, McCaffrey LD, Breitner JC. ADAPT Research Group, et al. Alzheimers Dement. 2009 Mar;5(2):93-104. doi: 10.1016/j.jalz.2008.09.004. Alzheimers Dement. 2009. PMID: 19328435 Free PMC article. Clinical Trial.
• Prevention of Alzheimer's disease: where we stand.
  Sano M. Sano M. Curr Neurol Neurosci Rep. 2002 Sep;2(5):392-9. doi: 10.1007/s11910-002-0064-8. Curr Neurol Neurosci Rep. 2002. PMID: 12169218 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Medical

  • MedlinePlus Health Information